19 October-30 November 2020
The 51st Union World Conference On Lung Health
REGISTER NOW

Sessions

All Sessions
keyboard_arrow_down
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Community Connect
  • Channel 1
  • Channel 2
  • Channel 3
  • Channel 4
  • Channel 5
  • Channel 6
  • Channel 7
  • E-posters
  • Workshops
E-posters
EP08-COVID-19 and TB: friends or foes?
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP08-COVID-19 and TB: friends or foes?
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP08-168-21-TB and Covid-19: Bangladesh perspective and challengesCovid-19 posed challenges in tuberculosis (TB) control in Bangladesh. During the first two months of the pandemic, a decrease in TB patients was reported. Patient-centred care was ensured by providing medicine to the patients and using telecommunication. Interim and long-term preparedness is required to resume enhanced momentum of TB control.
Mahfuza Rifat

EP08-169-21-The impact of Covid-19 on TB control in the Coast General Teaching and Referral Hospital, Mombasa County, KenyaKenya confirmed its first case of Covid-19 on 12 March 2020. In an effort to combat the pandemic Kenya, like the rest of the world, introduced some changes to its health service delivery. Being a country with a high tuberculosis (TB) burden, this had an impact on TB patients accessing care.
Cosmas Mwashumbe

EP08-170-21-Design and organisation of a temporary intensive care ward in response to the COVID-19 pandemicCOVID-19 placed a heavy burden on medical services. We designed and organised a temporary intensive care unit (ICU) ward within 48 hours. The space design, environmental cleaning and patients' daily care were the key steps to organising a practical ICU ward during the COVID-19 pandemic.
Xiangfeng Li

EP08-171-21-Trend analysis of exponential increase of COVID-19 cases in PakistanThe study was conducted to see the trends of COVID-19 among the Pakistani population. Pakistan started to feel the impact of the outbreak in mid-March with an increase in the number of cases at an alarming pace. So far, Sindh and Punjab province are the worst hit provinces with wide-spread community transmission.
Nadia Noreen

EP08-172-21-Sustaining TB services during the COVID-19 pandemic: experience and lessons learned from Nigeria in 2020Measures put in place to control the COVID-19 pandemic had the potential for interrupting tuberculosis (TB) services and erasing the gain made in TB control. Sustaining TB programmes during the COVID-19 pandemic became a priority of the national TB programme in Nigeria and the steps taken are documented and described in this study. 
Fadare Amos Omoniyi

EP08-175-21-Psychological experiences of mobile van TB screening team during COVID- 19 pandemic in Blantyre, MalawiResults have shown that health workers, working under MDU, experience several psychological challenges in this era of the COVID-19 pandemic and have compromised TB screening services. Therefore, mental health interventions are needed to mitigate these challenges. Self-coping style and psychological growth are important for health workers to maintain mental health.
Khwima Esther Mkalira

Loading...
Channel 5
SP-13-Deadly partners - COVID-19, non-communicable diseases and tobacco
event_note
Loading...
query_builder 16:30 - 17:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-13-Deadly partners - COVID-19, non-communicable diseases and tobacco
*Please scroll down for more information*
There has been a great deal of discussion about the potential relationship between COVID-19 and tobacco use. The underlying logic of a smoking-COVID-19 relationship is that smoking is an established risk factor for respiratory infections because it undermines the immunological response that a person can otherwise mount against a viral infection. Furthermore, there is a very strong relationship between smoking and non-communicable diseases that has emerged as a risk factor for COVID-19 severity and death. Studies from China show that the odds of progression towards serious illness are 14 times higher among people with a history of smoking.

16:30 - 16:35: Introduction

16:35 - 16:47: COVID-19, non-communicable diseases and impact on young peopleYoung people, especially those living with non-communicable diseases (NCDs) and its associated risk factors are vulnerable and susceptible to developing COVID-19 and its complications. This includes incomplete treatment regimens and restricted access to public health services for chronic conditions in times of lockdown and social distancing. Not to forget the major impact on mental health of young people. On the other hand, young people are also critical in promoting preventive messages for risk mitigation, disseminating information to their families, peer groups and community during this global crisis. Therefore, meaningful involvement of young people during the time of pandemic, as well as prevention of NCDs, is significant to the preparedness efforts, for not only the current, but also future public health crises.
Ishu Kataria

16:47 - 16:59: COVID-19 and lung healthCurrently evidence is lacking on how underlying lung disease will affect the severity and outcomes of COVID-19.  The longer term impact of COVID-19 on lung health is unknown but with large numbers of people requiring high flow oxygen and/or ventilation there are concerns regarding residual lung damage in COVID-19 survivors. The data on these areas will be reviewed as well as discussing what services need to be planned for COVID-19 survivors.
Grania Brigden

16:59 - 17:11: Deadly partners: COVID-19 and tobaccoTobacco smoking appears to be an important and entirely avoidable risk factor for a poorer prognosis in COVID-19. COVID-19 has not only severely constrained health systems, but also could have a cascading impact on the progress that countries were making towards different goals and targets of the United Nations Sustainable Development Goals (SDGs). With the looming danger of economic recession, it becomes even more vital to avert the huge financial cost of tobacco use to the global economy. The urgency to prioritise stronger action on comprehensive tobacco control is mandatory for optimal response to contain the COVID-19 pandemic.
Tara Singh Bam

17:11 - 17:23: Responding COVID-19 and non-communicable disease risk factorsTobacco causes eight million deaths every year and is a known risk factor for severe disease and death from many respiratory infections. Emerging evidence has suggested that smoking increases the risk of severe COVID-19 outcomes as well as the risk of death from COVID-19. However, in the absence of robust population studies to date, the association between smoking and infection with SARS CoV2 and between smoking and hospitalisation has not been reliably quantified.  This presentation will review the evidence on smoking and COVID-19 and will position the findings within the context of the wider literature and body of evidence. It will also look at risk communication of the findings on tobacco use and COVID-19 in the overall context of harms from tobacco use that are well established.
Hebe Gouda

17:23 - 17:50: Q&A session

Loading...
Channel 4
OA-14-COVID-19: the great disrupter
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-14-COVID-19: the great disrupter
*Please scroll down for more information*


12:30 - 12:35: Introduction


12:35 - 12:43: OA-14-585-22-The contribution of asymptomatic SARS-CoV-2 infections to transmission: a model-based analysis of the Diamond Princess outbreak A key gap in the understanding of SARS-CoV-2 infection is the extent to which individuals, who are experiencing asymptomatic infections, contribute to transmission. We used a transmission model of COVID-19 to estimate the proportion, infectiousness and contribution to transmission of asymptomatic infections during the outbreak on the Diamond Princess cruise ship.

Jon C. Emery

12:43 - 12:51: OA-14-586-22-Effect of COVID-19 on TB patient notification in Japan To investigate the impact of COVID-19 spread on tuberculosis (TB) patients notification in Japan, we compared and analysed the numbers of newly notified TB cases in the first quarter of 2019 and 2020.

Kazuhiro Uchimura

12:51 - 12:59: OA-14-587-22-Contacts or care? Impact of COVID-19-related disruption on TB burden COVID-19-related disruptions could increase tuberculosis (TB) burden through negatively affecting health services and/or decrease transmission through reduced social contact. The impact on incidence may depend on the balance between these opposing factors. However, any benefit of distancing on the number of TB deaths, is likely to be outweighed by health service disruption.

Rebecca C. Harris

12:59 - 13:07: OA-14-588-22-The impact of the COVID-19 epidemic on active TB case finding interventions in Nigeria: the KNCV TB Foundation Nigeria experience The COVID-19 epidemic impacted negatively on the tuberculosis (TB) programme in Nigeria. Results from two core, active TB case finding interventions being implemented by KNCV TB Foundation Nigeria - the TB surge and WoW campaigns - showed a progressive decline in achievement from the onset of COVID-19 to date.  

Bethrand Odume

13:07 - 13:15: OA-14-589-22-Willingness to test for TB among symptomatic community members in an era of COVID-19: findings from an exploratory mixed methods study from Anambra State, Nigeria We explored the impact of the COVID-19 response on willingness to undergo a tuberculosis (TB) test at the community level. The language of communication of the COVID-19 interventions seemed to evoke fear among community members and negatively affected their willingness to do a TB test, despite having symptoms of TB. 

Chukwuebuka Ugwu

13:15 - 13:23: OA-14-590-22-Use of virtual and community-delivery platforms to prevent multidrug-resistant TB treatment interruption during the national COVID-19 response: lessons from Uganda COVID-19 came with unprecedented disruptions in the management of multidrug-resistant tuberculosis. This was particularly the case as a nationwide lockdown was announced, restricting community care of drug-resistant tuberculosis where over 80% of the patients are.

Enock Kizito

13:23 - 13:31: OA-14-591-22-Implementation of psychosocial support services for patients with TB during the quarantine regime due to COVID-19 In response to the emergency, the Ukraine national tuberculosis (TB) programme and the project quickly reformatted the implementation of services for patients with TB in order to ensure continuous access to anti-TB treatment and psychosocial support during the quarantine regime due to COVID-19.

Tanya Ismagilova

13:31 - 13:50: Q&A


Loading...
Channel 5
SP-21-Engaging communities to address concurrent pandemics of TB and COVID-19
event_note
Loading...
query_builder 15:00 - 16:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-21-Engaging communities to address concurrent pandemics of TB and COVID-19
*Please scroll down for more information*
This symposium will utilise a range of perspectives to explore the critical role of community engagement to address tuberculosis (TB) and COVID-19. We will hear front line field notes from a community health worker (CHW) in South Africa. We will learn from experiences of applying knowledge from TB to deliver testing and contact tracing for COVID-19 through non-profit organisations in Peru and the U.S. We will examine strategies for engaging with policy makers to support CHWs and reduce the dual stigma of these infections. Finally, we will discuss partnerships with the media to maximise the impact of public health messaging to communities.

15:00 - 15:05: Introduction

15:05 - 15:15: Field notes: a frontline community health worker perspective on responding to TB in the time of COVID-19Community health workers (CHWs) play a critical role in supporting person-centred care, raising tuberculosis (TB) awareness, providing TB information in local languages to communities, and reaching missing people with TB who are not accessing health services and linking them to the health system. Each person has a human right to health and CHWs play a critical role in transforming the TB response to be equitable, rights-based and people-centred. Yet, CHWs are not provided with platforms to inform the TB response despite being experts on the healthcare needs of communities. Ms. Muedi will discuss insights from frontline CHWs, including identified gaps in the training and personal protective equipment offered to CHWs caring for people with TB, and the role of CHWs in the response to COVID-19.  
Portia Muedi

15:15 - 15:25: Prioritising partnerships: mobilising community health workers to fight COVID-19 in PeruSocios En Salud (SES) has partnered with the United States Agency for International Development to support Peru’s healthcare system to care for patients with COVID-19. Dr. Lecca will discuss how SES activated a community health worker network to safely conduct outreach visits to identify families needing clinical and social support in Peru’s hardest hit regions of Lima as well as a medical call centre to conduct telehealth consultations. Dr. Lecca will discuss how SES applied its many years of experience mobilising CHWs to contact public health education and contact tracing for TB in order to train CHWs to safely provide community-based care and education.  
Leonid Lecca

15:25 - 15:35: Bending the curve: leveraging experiences from TB care to contain COVID-19 in MassachusettsPartners In Health (PIH) is a non-governmental organisation that has built long standing relationships with ministries of health and communities in the world’s poorest settings, with the goal of providing the highest standard of care to all. As such, they are well positioned to tackle COVID-19, which is having a disproportionate impact on communities already affected by poverty and poor healthcare. Dr. Seung will discuss how PIH developed an ambitious response that sought to bend, rather than merely flatten, the curve of COVID-19 in Massachusetts and other U.S. states by applying lessons learned from TB with respect to testing, contact tracing, and supported quarantine and isolation. He will discuss the challenges of implementing rapid testing and addressing the social and economic needs of underserved communities, including the use of food and cash assistance, as part of a comprehensive response.
KJ Seung

15:35 - 15:45: Engaging policy makers to protect community health workersMs. Schoeman will discuss insights gained from leading a Gates Foundation funded project to empower community health workers (CHWs) to motivate for and contribute to person-centred tuberculosis (TB) care, by providing training in advocacy, media and communications. In response to stigma being identified as a major barrier in the TB care cascade, she helped to facilitate CHWs in Hammanskraal, Gauteng province, to develop community-focused theatre plays to address stigma.  She will discuss the challenges of building and maintaining strong relationships locally, provincially and nationally in order to secure support for in-service TB training of CHWs and for an implementation plan to accompany the Ward Based Primary Health Care Outreach Team policy that was recently released by the department of health. Finally, she will examine how TB Proof was able to leverage its TB advocacy partnerships to advocate to the South African government to impose a lockdown and #Masks4All policy to disrupt COVID-19 transmission.

Ingrid Schoeman

15:45 - 15:55: Partnering with the media to deliver public health messages to communitiesGovernments in high tuberculosis (TB) incidence settings like India have consistently failed to invest adequately in health and ensure funding of basic programmes to test, trace and treat TB. Concurrently, stigma and mistrust of government health systems have fuelled longstanding challenges to engage communities to participate in TB screening and to complete treatment. The COVID-19 pandemic has exacerbated social inequities with lockdowns and mass unemployment that have a disproportionate effect on the poorest, particularly while investment in testing, tracing and isolation remains inadequate. Ms. Krishnan will discuss insights she has gained from interviews with people affected by TB and other key stakeholders in the context of the COVID-19 pandemic. She will provide suggestions as to how public health professionals can engage communities with more effective messaging and interventions that are responsive to their needs. She will also address perceived gaps in current TB advocacy, from her unique perspective as a journalist.
Vidya Krishnan

15:55 - 16:20: Q&A session

Loading...
Channel 2
SS-09-Testing to turn the COVID-19 pandemic: the opportunity for TB
event_note
Loading...
query_builder 18:15 - 19:45 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-09-Testing to turn the COVID-19 pandemic: the opportunity for TB
*Please scroll down for more information*
Organised by: FIND and The Global Fund to Fight AIDS, Tuberculosis and Malaria.
FIND and The Global Fund are co-convenors of the Access to COVID-19 Tools (ACT) Accelerator Diagnostics Pillar – part of a  global collaboration to accelerate the development, production and equitable access to new COVID-19 tools including diagnostics. In addition  to developing new tests, the ACT Accelerator Diagnostics Pillar aims to strengthen low- and middle-income countries’ ability to procure, import, distribute tests  and manage data to assist governments in decision making. Tests developed to enable rapid diagnosis of tuberculosis (TB) are now being  used to diagnose COVID-19. Could global diagnostic networks and new COVID-19 tools be utilised to combat TB in the future?

18:15 - 18:19: Introduction


18:19 - 18:53: Panel discussion: TB, COVID-19 and ACT-A Dx – mitigating the impact and protecting TB gains Diagnostics are critical to any health response and essential to limit the spread of disease. However, greater innovation and  funding are needed to ensure tests can be deployed quickly and easily to everyone who needs one. In deploying new tools, programmes must  aim for integrated service delivery to balance supply and deployment constraints. FIND and The Global Fund are co-convenors of the Access  to COVID-19 Tools (ACT) Accelerator Diagnostics Pillar under which 50 new diagnostic tests have been evaluated. A new rapid antigen test  will soon be ready for roll out and 17 million tests have been delivered to low-and middle-income countries. The ACT-Accelerator experience provides vital lessons on  what a blueprint for successful pandemic preparedness and response could look like for diagnostics. What lessons can we learn for tuberculosis (TB), which is already experiencing the knock-on impact of COVID-19, and how do we protect our gains in TB while successfully beating the pandemic?

Catharina Boehme
John Nkengasong
Kuldeep Singh Sachdeva
Peter Sands

18:53 - 19:03: TB tests being 'repurposed' for COVID-19: experience with Truenat, GeneXpert, digital X-rays and next-generation  sequencing The COVID-19 pandemic has seen existing diagnostics for tuberculosis (TB) being repurposed or used to diagnose COVID-19. Cepheid  Inc’s GeneXpert® MTB/RIF - for the rapid diagnosis of TB and detection of rifampicin-resistance - is being used to run a newly developed  COVID-19 test. Similarly, Indian diagnostic manufacturer, Molbio, whose Truenat™ test was recently endorsed by the World Health Organization received approval  from India’s regulatory authority for a Truenat COVID-19 test, expanding the number of existing diagnostics platforms repurposed for COVID-19. Additionally, digital chest Xray can be deployed along with artificial intelligence-based tools for both TB and COVID-19.  Leveraging ongoing efforts in enabling next-generation sequencing solutions for drug-resistant TB detection under the Unitaid-funded  Seq&Treat project, FIND has compiled a landscape and a preliminary assessment of sequencing utility and capacity in low-and middle-income countries for COVID-19 surveillance and management. We’ll share in-country implementers' experience repurposing TB tests for COVID-19.

Morten Ruhwald

19:03 - 19:13: Ending TB amid the COVID-19 pandemic: a community-led response The COVID-19 pandemic has had tremendous impact on tuberculosis (TB) programmes and activated disruptions along the care spectrum, from screening to diagnosis to the treatment of people with TB. While efforts have been made through the contribution of the Global Fund and stakeholders worldwide, impactful gains were undone. While barriers were being addressed there was an increase in the barriers faced, including  access to services, along with heightened stigma and the dual stigma of COVID-19 and TB. There is a need for meaningful engagement and for strengthening community engagement and linkages in order to address barriers collectively and to find solutions. Community systems and community-led  monitoring can support the implementation of catch-up plans so that efforts in finding the missing people with TB can be reinforced and barriers can be mitigated.
This session highlights experiences of civil society and partners and their role in the mitigation of the impact of COVID-19 on TB and on the road ahead.

Carol Nawina (Nyirenda) Kachenga

19:13 - 19:23: Access to TB diagnostic services during COVID-19: experience from South Africa In many of the countries most heavily affected by HIV, tuberculosis (TB) and malaria, the knock-on impact of COVID-19 on these three  diseases, in terms of incremental deaths, may outweigh the direct impact of the virus. The Global Fund is already witnessing the impact of  COVID-19 on the fight against HIV, TB and malaria across the countries where itinvests. For example, TB laboratory services are under acute  pressure, with 20% experiencing high or very high levels of disruption, with many of the advanced diagnostics instruments put in place to  diagnose TB now being used for testing for COVID-19. We’ll hear from South Africa – a country with a high TB and HIV burden which is now addressing  the deadly pandemic - on scale-up of COVID-19 testing and integration of testing services for COVID-19 and TB.

Wendy Stevens

19:23 - 19:45: Q&A session


Loading...
Channel 3
SP-41-Preventing human rights abuses in the digitisation of the TB and COVID-19 responses
event_note
Loading...
query_builder 11:00 - 12:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-41-Preventing human rights abuses in the digitisation of the TB and COVID-19 responses
*Please scroll down for more information*
The digitalisation of the tuberculosis (TB) response is increasing the amount and kind of data produced and used by public and private health officials. Digital tools for active case finding and adherence, as well as artificial intelligence algorithms, are now being repurposed or broadened for use in the COVID-19 response. Lessons from the HIV and TB responses, for protections of privacy and confidentiality and elimination of stigma and discrimination, must be leveraged for COVID-19. This session will examine the normative, legal and technical aspects of using digital technologies in the TB and COVID-19 responses.  

11:00 - 11:05: Introduction

11:05 - 11:17: Big data in the TB and COVID-19 reponses: a neocolonial and human rights analysisWith the advent of big data comes increased potential for exacerbating disparity through data both directly and indirectly. The production of personal data in high tuberculosis (TB) burden countries, in particular, must be considered in light of their colonial histories. Importantly, interventions intended to eliminate TB at global and national levels are ushering in a new era of data commodification, colonisation, and surveillance in the name of public health. This, in turn, raises critical concerns for the human rights of people affected by TB, many of whom belong to vulnerable or marginalised groups. Importantly, examining the relationship between TB, data surveillance and human rights law does more than illuminate potential pitfalls – it also foreshadows possible solutions.
Kat Albrecht

11:17 - 11:29: Watch out for DAT Trojan horse: DATs v. DOT for TB TreatmentThe proliferation of digital adherence technologies (DATs) in the tuberculosis (TB) response is thought to signal a departure from the longstanding approach of directly observed therapy (DOT). But are the two approaches really any different? This talk will consider whether DATs, rather than representing a true break from DOT, are instead a Trojan horse of sorts. That is, do DATs simply prolong the global community’s reliance on an outdated treatment paradigm, while introducing a whole new set of concerns? This question must be considered in light of the fact that DATs will generate massive amounts of personal data of people affected by TB - some of the most vulnerable people in our communities - for use by government and, in some cases, private health authorities.
Brian Citro

11:29 - 11:41: The risks of digitisation for surveillance and contract tracing for TB and COVID-19Apart from debate on COVID-19, conversations on privacy and data protection have gained momentum over the last few months. Questions have arisen on whether strategies to manage COVID-19 have clawed back on gains made in protection of fundamental rights and freedoms especially the right to privacy. Also, whether such strategies have been well thought out and whether they are in proportion in view of their purpose. There is genuine concern that the surveillance mechanisms that have been adopted by states to deal with the pandemic have gone, or will go, beyond their legal purpose. Surveillance mechanisms have gradually moved from physical surveillance by healthcare professionals to surveillance by security agents and digital surveillance using mobile phone data. Hence, there is need to interrogate what form of digital contact tracing would not pose unnecessary risks to the protection and promotion of fundamental rights and freedoms.
Mugambi Laibuta

11:41 - 11:53: Opportunities and risks for digital technologies in TB community-led monitoringThe reliance on comprehensive, high quality and timely data and information on the barriers faced by people affected by tuberculosis (TB) in accessing essential TB services has given rise to the need for community-led monitoring (CLM) of the TB response and digital CLM solutions.  Intended for collecting, exchanging and making accessible data and information about the TB response as evidence for action, the ultimate aim of CLM is to close the gap in the number of people who fail to receive TB care. Ensuring rights and protections of populations engaged in its pursuit is an ethical and programmatic imperative. This talk will consider the opportunities for digital solutions in CLM, the ethical dilemmas that arise in CLM data management and potential solutions.  
Caoimhe Smyth

11:53 - 12:18: Q&A session

Loading...
Channel 3
SP-43-COVID-19 in pregnant women
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-43-COVID-19 in pregnant women
*Please scroll down for more information*
Immunologic and physiologic changes occur rapidly in pregnancy and may impact pathogenesis, clinical presentation and transmission of SARS-CoV-2, complicating management and leading to poor maternal-foetal outcomes in some cases. Recent reports of asymptomatic women admitted for delivery services have led some settings to initiate universal screening. This symposium will feature emerging research on the immunology of COVID-19 in pregnancy and the differences in clinical presentation and management - including treatment options, policies for safe pregnancy and potential research priorities - which will improve our understanding of this devastating pandemic in all populations.

12:30 - 12:35: Introduction

12:35 - 12:45: Pathogenesis and immunology of COVID-19 in pregnant womenThe Washington State COVID-19 in Pregnancy Collaborative was established to identify known pregnant COVID-19 cases from 16 major tertiary referral centres and community hospitals representing >40% of the ~86,000 annual deliveries in Washington State. In order to improve our understanding of how SARS-CoV-2, the virus that causes COVID-19 impacts the health of pregnant women and their newborns, a multipronged approach is needed, including population-based efforts to describe pregnancy outcomes among women with COVID-19, as well as detailed immunologic studies including placental innate immune responses to SARS-CoV-2. We will discuss the pathogenesis and immunology of COVID-19 in pregnancy, including lessons learned from other emerging infectious diseases.
Kristina Adams Waldorf

12:45 - 12:55: Pregnancy and postpartum outcomes of COVID-19 in New York City: a multicentre prospective cohort studyOver 700,000 confirmed cases of SARS-CoV-2 and 20,000 deaths from COVID-19 have occurred in New York City, making it the epicentre of the infection with fatalities topping that of many European countries. Early in the pandemic, pregnant women were noted to be asymptomatic carriers of SARS-CoV-2, and New York rapidly instated a universal screening programme. In this talk, the findings from this prospective cohort will be discussed, including maternal presentation, obstetric and neonatal outcomes, and placental pathology associated with COVID-19 infection. We will also discuss the evolution of maternal symptoms throughout the course of labour and the postpartum period, with implications for postpartum care.
Malavika Prabhu

12:55 - 13:05: Use of remdesivir for moderate to severe COVID-19 in pregnancyRemdesivir is one of the promising treatments being investigated for the treatment of COVID-19. Gilead, the manufacturer of remdesivir, allowed compassionate use of remdesivir for pregnant women with moderate to severe COVID-19. In this talk, they will present the experience of 86 pregnant women, who received compassionate-use remdesivir, including baseline demographic and clinical characteristics, their time to recovery and time to discharge. For women who delivered, birth outcomes and postpartum complications will be characterised. This data will be important groundwork for future clinical trials that include pregnant women.
Moupali Das

13:05 - 13:15: Crowd-sourcing knowledge for COVID-19 in pregnancy with the World Health Organization registry: potential for maternal TB and beyond?To understand how SARS-CoV-2 infection during pregnancy impacts COVID and pregnancy and postpartum outcomes, the World Health Organization (WHO) has developed a standardised clinical registration platform with a specific module targeting pregnant women. Further, a standardised research protocol has been designed. The protocol allows each site to adapt, based on resource availability and local circumstances, and provides the option to focus on national analyses or participate in pooling. Knowledge of tuberculosis (TB) in pregnancy is still scarce. This presentation will discuss possibilities to build on experiences through different methods related to SARS-CoV-2 and possible implication to TB.
Anna Thorson

13:15 - 13:50: Q&A session

Loading...
Channel 2
SS-11-TB in the COVID-19 era in India
event_note
Loading...
query_builder 18:15 - 19:45 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-11-TB in the COVID-19 era in India
*Please scroll down for more information*
Organised by: Mylan Pharmaceuticals Pvt. Ltd
COVID-19 pandemic has presented us with a global health crisis. The national programmes to combat TB need to be actively engaged ensuring an effective, rapid response to COVID-19 whilst maintaining TB services. This satellite session discusses relationship between TB/COVID, impact of COVID- 19 on TB management, strategies adopted to mitigate them and how policies need to be shaped considering the dual morbidity of TB and COVID going forward.
Target audience: pulmonologists, infectious disease specialists, c         consultant physicians, programme managers, policy-makers


18:15 - 18:20: Introduction


18:20 - 18:40: Challenges in the management of TB during the pandemic COVID-19 pandemic has had a significant impact in the delivery of various tuberculosis prevention, surveillance, and treatment programmes. Lockdown and public health guidelines have resulted in tough challenges in traditional management of tuberculosis. This talk presents the challenges in the managing TB during the pandemic.

Kuldeep Singh Sachdeva

18:40 - 19:00: Adapting TB services during COVID-19 As the first cases of COVID-19 were identified in India, the provision of essential services in Mumbai (including those for TB/DR-TB), were heavily affected by lockdown regulations and reassignment of health care workers to COVID-19. To ensure continuity of care, TB services were adapted to protect both health care workers and patients, focusing on infection prevention and control measures, screening, linkage to COVID-19 care and the avoidance of non-essential visits. This talk summarizes the main challenges faced during this adaptation of TB services and the proposed solutions.

Vikas Oswal S

19:00 - 19:20: Preparing tertiary TB institute for COVID-19: challenges and Solution It is known that COVID-19 and TB have similar clinical features and presentations. There exist subtle differences between the two disease processes. Early evidence suggests patients with latent TB and established disease have an increased risk of the SARS-CoV-2 infection and predisposition towards developing severe COVID-19 pneumonia. This talk will describe the COVID-19 and TB relationship.

Rupak Singla

19:20 - 19:30: Closing remarks

Digambar Behera

19:30 - 19:45: Q&A session


Loading...
Processing. Please wait.
Loading...